Metsera (NASDAQ:MTSR) Downgraded by Wall Street Zen to "Sell"

Key Points

• Metsera has been downgraded by Wall Street Zen from a "hold" to a "sell" rating, indicating a shift in market sentiment toward the stock.
• Various analysts have provided mixed ratings on Metsera, with one indicating a strong-buy and others maintaining buy or overweight ratings, highlighting the differing perspectives within the market.
• Metsera's stock has experienced significant volatility, with a 12-month low of $12.30 and a high of $54.47, reflecting its fluctuating value in the biopharmaceutical sector.

Metsera (NASDAQ:MTSR - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Tuesday.

Several other research analysts also recently commented on the company. Leerink Partnrs raised Metsera to a "strong-buy" rating in a report on Tuesday, September 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Bank of America boosted their price objective on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Finally, Wells Fargo & Company initiated coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $63.50.

Metsera Price Performance

NASDAQ MTSR opened at $53.58 on Tuesday. Metsera has a twelve month low of $12.30 and a twelve month high of $54.47. The business's fifty day moving average is $35.71 and its 200 day moving average is $29.35.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Hedge Funds Weigh In On Metsera

Several institutional investors have recently bought and sold shares of MTSR. Bank of New York Mellon Corp purchased a new position in Metsera in the first quarter valued at approximately $884,000. New York State Common Retirement Fund purchased a new position in Metsera in the first quarter valued at approximately $131,000. Alphabet Inc. purchased a new position in Metsera in the first quarter valued at approximately $135,059,000. Massachusetts Financial Services Co. MA purchased a new position in Metsera in the first quarter valued at approximately $13,111,000. Finally, Jennison Associates LLC purchased a new position in Metsera in the first quarter valued at approximately $9,679,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.